Close Menu

NEW YORK (GenomeWeb) – Having recently kicked off a beta testing program for its miniaturized RNAi screening technology, startup Persomics is aiming for a full commercial launch of its first products before the end of the year.

In the meantime, the company is working to strike deals with the various life science firms that will provide the siRNA content for the plates that are the foundation of its technology, as well as providers of high-content imaging platforms interested in optimizing their systems for use with the plates, Persomics COO Mike Sjaastad told GenomeWeb this week.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

NPR reports that the patient who underwent a CRISPR-based treatment for sickle cell disease is doing well.

Resistance to ash dieback disease among some UK ash trees appears polygenic, the Independent reports.

In Nucleic Acids Research this week: sequencing strategy for flash-frozen brain tissue bank samples, new version of ChlamDB, and more.

A UK woman is suing three National Health Service Trusts for not telling her about her father's Huntington's disease diagnosis, the BBC reports.